Byron Capital analyst Douglas Loe says that while there are several competitors conducting head and neck cancer studies, Reolysin is particularly well positioned because but few “truly novel” agents are in advanced clinical testing.
About Nick WaddellCantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
